The risk of atrial fibrillation (AF) appears to be elevated among patients with a history of cancer, particularly those with prostate cancer, according to a study presented at ACC.20.
Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Patients with previously treated advanced or metastatic clear cell renal cell carcinoma (RCC) appear to derive greater overall survival (OS) benefit with nivolumab compared with everolimus, according to final results of the phase III CheckMate 025* trial presented at ASCO GU 2020.
Stereotactic ablative radiotherapy (SABR) has shown promising results in primary renal cell carcinoma (RCC) in recent trials and has become a treatment option for patients with inoperable primary RCC or tumours in solitary kidney, said Dr Shankar Siva of the Peter MacCallum Cancer Centre of Melbourne, Australia, at the Uro-Oncology Asia 2020 conference.